Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.

BMO Capital Markets agreed to pay more than $40 million to settle U.S. Securities and Exchange Commission charges it failed ...

Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer ...

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant ...

The ASX slumped further on Monday, with the S&P/ASX 200 index down 1.23% following strong US jobs data, dashing hopes of an ...

Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers ...

Philadelphia, Pennsylvania-- (Newsfile Corp. - January 10, 2025) - Kehoe Law Firm, P.C. is investigating potential securities class action claims on behalf of investors of TransMedics Group, Inc.

Shares of TransMedics Group (NASDAQ: TMDX) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came ...

Short seller Scorpion Capital disclosed a short position in TransMedics Group Inc (NASDAQ:TMDX) accusing the organ transplant tech. company of fraudulent practices, including kickbacks, billing fraud, ...

EST TransMedics (TMDX) down 10% to $65.39 after Scorpion Capital short reportStay Ahead of the Market:Discover outperforming stocks and ...